AmpliPhi Biosciences

OverviewSuggest Edit

AmpliPhi Biosciences Corporation is a biotechnology company that focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company is working on products for the treatment of Staphylococcus aureus and pseudomonas aeruginosa lung infections. AmpliPhi Biosciences merged with C3J Therapeutics to form Armata Pharmaceuticals.

StateClosed
TypePrivate
Founded1989
HQSan Diego, CA, US
Websiteampliphibio.com

Latest Updates

Employees (est.) (Mar 2019)30(-3%)
Revenue (FY, 2014)$409 K
Share Price (May 2019)$0.3(-20%)
Cybersecurity ratingAMore

Key People/Management at AmpliPhi Biosciences

Paul Grint

Paul Grint

CEO
Steve Martin

Steve Martin

CFO
Igor Bilinsky

Igor Bilinsky

COO
Sandra Morales

Sandra Morales

Vice President of Research
Alexander Gaidamaka

Alexander Gaidamaka

Vice President of Chemistry, Manufacturing and Controls
Carrie-Lynn Langlais Furr

Carrie-Lynn Langlais Furr

Vice President of Regulatory Affairs and Program Management
Show more

AmpliPhi Biosciences Office Locations

AmpliPhi Biosciences has offices in San Diego, Richmond, Brookvale and Ljubljana
San Diego, CA, US (HQ)
3579 Valley Centre Dr # 300
Richmond, VA, US
Biotech Center, 800 E Leigh St
Brookvale, AU
27 Dale St
Ljubljana, SI
259 Litijska cesta
Show all (4)

AmpliPhi Biosciences Financials and Metrics

Summary Metrics

Founding Date

1989

AmpliPhi Biosciences total Funding

$44 m

AmpliPhi Biosciences latest funding size

$13 m

Time since last funding

7 years ago

AmpliPhi Biosciences investors

AmpliPhi Biosciences's latest funding round in March 2015 was reported to be $13 m. In total, AmpliPhi Biosciences has raised $44 m
Show all financial metrics

AmpliPhi Biosciences Revenue

AmpliPhi Biosciences's revenue was reported to be $409 k in FY, 2014
USD

Net income (Q1, 2020)

(5.1m)

Cash (31-Mar-2020)

24.2m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

409.0k

Revenue growth, %

16%(45%)

General and administrative expense

6.9m6.4m8.4m7.6m5.7m9.3m

R&D expense

5.8m4.0m5.7m2.9m4.9m9.8m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

101.0k103.0k102.0k

General and administrative expense

1.6m2.0m1.7m1.4m1.6m1.6m2.6m2.5m1.8m1.9m2.8m1.6m1.6m1.4m1.3m2.1m2.1m3.8m2.2m

R&D expense

1.0m1.9m1.8m972.0k1.1m728.0k2.0m1.2m1.7m1.5m1.1m1.5m1.7m361.0k1.5m3.1m3.0m2.8m

Operating expense total

2.6m3.8m3.5m2.4m2.7m2.3m4.6m3.7m3.4m3.4m3.9m1.6m3.1m3.1m1.6m3.6m5.2m6.8m4.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.6m9.4m5.7m5.1m8.2m6.0m

Accounts Receivable

100.0k125.0k25.0k

Prepaid Expenses

339.0k521.0k253.0k251.0k622.0k

Current Assets

7.0m10.0m6.4m5.4m8.4m6.7m
Quarterly
USDQ1, 2014

Financial Leverage

-1.4 x
Show all financial metrics

AmpliPhi Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

AmpliPhi Biosciences Online and Social Media Presence

Embed Graph

AmpliPhi Biosciences News and Updates

C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

MARINA DEL REY, Calif., May 9, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

NEW YORK, April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like additional...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

NEW YORK, March 27, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of AmpliPhi Biosciences Corporation...

Bacteriophage market size, share and Forecast 2026: Leading players AmpliPhi Biosciences Corporation, EnBiotix, Phage Biotech Ltd., Fixed-Phage Limited, InnoPhage, Pherecydes Pharma Company

The global bacteriophage market held US$ 567.9 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 3.9% during the forecast period from 2018 to 2026. Bacteriophages are estimated as the most widely distributed and varied entities in the biosphere. Posted via Industry Today. Foll…

AmpliPhi Biosciences Blogs

Research Associate – Formulation

About this Position: The Research Associate I position will report to the Senior Scientist. The RA will assist with completing individual formulation development projects in support of Armata’s bacteriophage pipeline programs. Duties will include assembly of study designs, performance of laboratory …

Assoc. Scientist/Scientist Phage & Bacterial Genetics, Engineering & Synthetic Biology

About this Position: This position will evaluate existing engineering methods and devise new ones in order to build improved phages as needed per the goals of our clinical development programs. The work will involve genetically altering phages and their hosts to improve their safety, efficacy or man…

Quality Assurance (QA) Associate

About this Position: The Quality Assurance (QA) Associate, under the direction of the Associate Director of QA & Regulatory Affairs, will support process development, manufacturing and clinical operations by assisting in the implementation and maintenance of quality systems that ensure complianc…

Bacteria-eating viruses could provide a route to stability in cystic fibrosis: Phage therapy is broadening the treatment landscape for people with drug-resistant infections.

The post Bacteria-eating viruses could provide a route to stability in cystic fibrosis: Phage therapy is broadening the treatment landscape for people with drug-resistant infections. appeared first on Armata Pharmaceuticals.
Show more

AmpliPhi Biosciences Frequently Asked Questions

  • When was AmpliPhi Biosciences founded?

    AmpliPhi Biosciences was founded in 1989.

  • Who are AmpliPhi Biosciences key executives?

    AmpliPhi Biosciences's key executives are Paul Grint, Steve Martin and Igor Bilinsky.

  • How many employees does AmpliPhi Biosciences have?

    AmpliPhi Biosciences has 30 employees.

  • Who are AmpliPhi Biosciences competitors?

    Competitors of AmpliPhi Biosciences include Brii Biosciences, Molecular Partners and Nordic Nanovector.

  • Where is AmpliPhi Biosciences headquarters?

    AmpliPhi Biosciences headquarters is located at 3579 Valley Centre Dr # 300, San Diego.

  • Where are AmpliPhi Biosciences offices?

    AmpliPhi Biosciences has offices in San Diego, Richmond, Brookvale and Ljubljana.

  • How many offices does AmpliPhi Biosciences have?

    AmpliPhi Biosciences has 4 offices.